Skip to main content
SpringerLink
Log in

Rituximab biosimilar: no increased risk of hypersensitivity reactions

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Jourdain H, et al. Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System. BioDrugs : 6 Mar 2023. Available from: URL: https://doi.org/10.1007/s40259-023-00584-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rituximab biosimilar: no increased risk of hypersensitivity reactions. Reactions Weekly 1949, 12 (2023). https://doi.org/10.1007/s40278-023-35992-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-35992-x

Search

Navigation